Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25312339 | 0.85 | NR1H2 (0.47) | ALDH1A1NR1H2NR1H3SMN1; SMN2 | |
| SCHEMBL1536762 | 0.84 | TSHR (0.38) | MMP2ANPEPTSHRALDH1A1SLC6A2 | |
| SCHEMBL28060561 | 0.82 | NR1H2 (0.53) | ALDH1A1NR1H2NR1H3SMN1; SMN2 | |
| SCHEMBL318353 | 0.82 | MMP2 (0.47) | MMP2ANPEPTSHRALDH1A1POLB | |
| SCHEMBL30686137 | 0.82 | MMP2 (0.47) | MMP2ANPEPTSHRALDH1A1POLB | |
| SCHEMBL18952875 | 0.81 | POLB (0.35) | TSHRPOLB | |
| SCHEMBL26694944 | 0.81 | POLB (0.35) | TSHRPOLB | |
| SCHEMBL21045619 | 0.81 | POLB (0.35) | TSHRPOLB | |
| SCHEMBL8402776 | 0.80 | AGTR2 (0.47) | — | |
| SCHEMBL919018 | 0.80 | AGTR2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2023-04-27 | — | — | US | disclosed |
| EP-3768256-A1 | PAN-TROPIC ENTRY INHIBITORS | Emory University (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020081917-A1 | ΒETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2019183133-A1 | Pan-Tropic Entry Inhibitors | EMORY UNIVERSITY (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-2318408-A2 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010011772-A2 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131402-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | MMP2 2331/4885ANPEP 2421/4885TSHR 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.